
ALT Research in context panel for a paper published in The Lancet Regional Health - Europe entitled \"GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study\". Copyright: 2026 The Author(s). Published by Elsevier Ltd. CC BY 4.0.

ALT Glucagon-like peptide–1 (GLP-1) receptor agonists are among the most effective treatments for obesity and other metabolic disorders. With widespread use of these drugs, it has become clear that their effects go well beyond health conditions traditionally linked to metabolism, affecting multiple other organ systems, particularly the brain. Continued research in this field has also expanded beyond the GLP-1 receptor as a target, with the development of additional drugs and combinations to help optimize patient care. Illustration: C. Bickel/Science



















